company background image
BVXP

BioventixAIM:BVXP Stock Report

Last Price

UK£31.30

Market Cap

UK£163.1m

7D

1.3%

1Y

-29.7%

Updated

21 Jan, 2022

Data

Company Financials +
BVXP fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance3/6
Financial Health6/6
Dividends5/6

BVXP Stock Overview

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide.

Price History & Performance

Summary of all time highs, changes and price drops for Bioventix
Historical stock prices
Current Share PriceUK£31.30
52 Week HighUK£45.49
52 Week LowUK£30.00
Beta0.36
1 Month Change-6.57%
3 Month Change-14.83%
1 Year Change-29.66%
3 Year Change-0.63%
5 Year Change119.65%
Change since IPO1,505.13%

Recent News & Updates

Mar 29
Should Bioventix PLC (LON:BVXP) Be Part Of Your Dividend Portfolio?

Should Bioventix PLC (LON:BVXP) Be Part Of Your Dividend Portfolio?

Is Bioventix PLC ( LON:BVXP ) a good dividend stock? How can we tell? Dividend paying companies with growing earnings...

Mar 14
Is Now The Time To Put Bioventix (LON:BVXP) On Your Watchlist?

Is Now The Time To Put Bioventix (LON:BVXP) On Your Watchlist?

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...

Feb 27
What Does Bioventix's (LON:BVXP) CEO Pay Reveal?

What Does Bioventix's (LON:BVXP) CEO Pay Reveal?

The CEO of Bioventix PLC ( LON:BVXP ) is Peter Harrison, and this article examines the executive's compensation against...

Shareholder Returns

BVXPGB BiotechsGB Market
7D1.3%-4.7%-0.5%
1Y-29.7%-14.6%8.7%

Return vs Industry: BVXP underperformed the UK Biotechs industry which returned -14.6% over the past year.

Return vs Market: BVXP underperformed the UK Market which returned 8.7% over the past year.

Price Volatility

Is BVXP's price volatile compared to industry and market?
BVXP volatility
BVXP Average Weekly Movement4.0%
Biotechs Industry Average Movement6.5%
Market Average Movement5.0%
10% most volatile stocks in GB Market10.7%
10% least volatile stocks in GB Market2.5%

Stable Share Price: BVXP is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: BVXP's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200312Peter Harrisonhttps://www.bioventix.com

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services.

Bioventix Fundamentals Summary

How do Bioventix's earnings and revenue compare to its market cap?
BVXP fundamental statistics
Market CapUK£163.05m
Earnings (TTM)UK£6.73m
Revenue (TTM)UK£10.93m

24.2x

P/E Ratio

14.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BVXP income statement (TTM)
RevenueUK£10.93m
Cost of RevenueUK£817.45k
Gross ProfitUK£10.11m
ExpensesUK£3.38m
EarningsUK£6.73m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)1.29
Gross Margin92.52%
Net Profit Margin61.58%
Debt/Equity Ratio0.0%

How did BVXP perform over the long term?

See historical performance and comparison

Dividends

4.6%

Current Dividend Yield

81%

Payout Ratio

Valuation

Is Bioventix undervalued compared to its fair value and its price relative to the market?

24.22x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: BVXP (£31.3) is trading above our estimate of fair value (£26.83)

Significantly Below Fair Value: BVXP is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BVXP is good value based on its PE Ratio (24.2x) compared to the UK Biotechs industry average (44.5x).

PE vs Market: BVXP is poor value based on its PE Ratio (24.2x) compared to the UK market (19.1x).


Price to Earnings Growth Ratio

PEG Ratio: BVXP's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: BVXP is overvalued based on its PB Ratio (13.8x) compared to the GB Biotechs industry average (5.6x).


Future Growth

How is Bioventix forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-1.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BVXP's earnings are forecast to decline over the next 3 years (-1% per year).

Earnings vs Market: BVXP's earnings are forecast to decline over the next 3 years (-1% per year).

High Growth Earnings: BVXP's earnings are forecast to decline over the next 3 years.

Revenue vs Market: BVXP's revenue (0.8% per year) is forecast to grow slower than the UK market (4.9% per year).

High Growth Revenue: BVXP's revenue (0.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BVXP's Return on Equity is forecast to be very high in 3 years time (58.8%).


Past Performance

How has Bioventix performed over the past 5 years?

11.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BVXP has high quality earnings.

Growing Profit Margin: BVXP's current net profit margins (61.6%) are lower than last year (69.8%).


Past Earnings Growth Analysis

Earnings Trend: BVXP's earnings have grown by 11.4% per year over the past 5 years.

Accelerating Growth: BVXP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: BVXP had negative earnings growth (-6.5%) over the past year, making it difficult to compare to the Biotechs industry average (50.7%).


Return on Equity

High ROE: BVXP's Return on Equity (56.9%) is considered outstanding.


Financial Health

How is Bioventix's financial position?


Financial Position Analysis

Short Term Liabilities: BVXP's short term assets (£11.5M) exceed its short term liabilities (£1.0M).

Long Term Liabilities: BVXP's short term assets (£11.5M) exceed its long term liabilities (£78.1K).


Debt to Equity History and Analysis

Debt Level: BVXP is debt free.

Reducing Debt: BVXP has not had any debt for past 5 years.

Debt Coverage: BVXP has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: BVXP has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Bioventix current dividend yield, its reliability and sustainability?

4.57%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: BVXP's dividend (4.57%) is higher than the bottom 25% of dividend payers in the UK market (1.37%).

High Dividend: BVXP's dividend (4.57%) is in the top 25% of dividend payers in the UK market (4.04%)


Stability and Growth of Payments

Stable Dividend: BVXP's dividends per share have been stable in the past 10 years.

Growing Dividend: BVXP's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: At its current payout ratio (81.3%), BVXP's payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: BVXP's dividends in 3 years are not forecast to be well covered by earnings (96.9% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.0yrs

Average board tenure


CEO

Peter Harrison (63 yo)

no data

Tenure

UK£303,637

Compensation

Mr. Peter John Harrison, MA, serves as the Chief Executive Officer of Bioventix PLC. Mr. Harrison has worked in the field of antibody technology since 1986 and has extensive experience of the development a...


CEO Compensation Analysis

Compensation vs Market: Peter's total compensation ($USD411.71K) is about average for companies of similar size in the UK market ($USD573.76K).

Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: BVXP's board of directors are considered experienced (8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BVXP insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Bioventix PLC's employee growth, exchange listings and data sources


Key Information

  • Name: Bioventix PLC
  • Ticker: BVXP
  • Exchange: AIM
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: UK£163.052m
  • Shares outstanding: 5.21m
  • Website: https://www.bioventix.com

Number of Employees


Location

  • Bioventix PLC
  • 27–28 Eastcastle Street
  • London
  • Greater London
  • W1W 8DH
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/21 21:22
End of Day Share Price2022/01/21 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.